Bone marrow CD14+CD206+ M2-like monocyte-macrophages as a potential complementary biomarker for bone marrow MRD in high-risk neuroblastoma
Open Access
- 28 October 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1904750
Abstract
Neuroblastoma (NB) is a highly aggressive pediatric malignancy, frequently associated with a substantial risk of bone marrow metastasis and recurrence. The persistence of minimal residual disease (MRD) remains the primary obstacle to successful treatment outcomes. Bone marrow minimal residual disease (MRD) assessment in high-risk neuroblastoma primarily relies on the direct detection of residual tumor cells. However, the accompanying immune-microenvironmental changes remain incompletely characterized. In this study, GD2-directed immunocytochemistry, complemented by GD2-based flow cytometry, was used for the reference classification of bone marrow disease status in a cohort of 143 patients with high-risk neuroblastoma. We evaluated a panel of peripheral blood biomarkers, identifying NSE, CRP, FBG, and D-dimer as exhibiting significant differences between MRD-positive and MRD-negative groups; however, these biomarkers demonstrated limited diagnostic utility, with area under the curve (AUC) values below 0.7. Importantly, bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed discriminatory ability for GD2-defined bone marrow MRD status (AUC = 0.794), with an optimal threshold of 1.71×10 4 /mL. Additionally, the proportion of CD14 + CD206 + macrophages showed a positive correlation with GD2 positivity in bone marrow samples. These findings suggest that bone marrow CD14 + CD206 + M2-like monocyte-macrophages showed potential as an auxiliary immune biomarker associated with bone marrow MRD status in high-risk NB. These findings require validation in larger, independent cohorts.Keywords
This publication has 31 references indexed in Scilit:
- Impact of diagnostic and end‐of‐induction Curie scores with tandem high‐dose chemotherapy and autologous transplants for metastatic high‐risk neuroblastoma: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2023
- The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectPediatric Blood & Cancer, 2020
- The challenge of defining “ultra‐high‐risk” neuroblastomaPediatric Blood & Cancer, 2018
- Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group databaseEuropean Journal of Cancer, 2016
- Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects2015
- Alternative Activation of Macrophages: Mechanism and FunctionsImmunity, 2010
- Inflammation and cancer: back to Virchow?The Lancet, 2001
- Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982–1992European Journal of Cancer, 2000
- Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulatingCancer Immunology, Immunotherapy, 2000
- Serum neuron‐specific enolase in children with neuroblastoma. Crelationship to stage and disease courseCancer, 1986